Clinical Research Directory
Browse clinical research sites, groups, and studies.
Antidiabetic Medications and Risk of Cancer
Sponsor: University of Pecs
Summary
A retrospective analysis was conducted based on data of the National Health Insurance Fund in Hungary. Overall cancer risk and site-specific cancer risks were analysed in a target trial emulation design when comparing all available antidiabetic therapies to MET and monotherapies and primary combination therapies against each other. The model used in the analysis was corrected for age, gender, co-morbidities, selected cardiovascular medications and inpatient and outpatient visits.
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
OBSERVATIONAL
Enrollment
74799
Start Date
2025-03-15
Completion Date
2025-12-30
Last Updated
2026-06-05
Healthy Volunteers
No
Conditions
Interventions
Metformin
Metformin monotherapy
sulphonylurea
SU monotherapy
DPP-4 inhibitor
DPP-4 inhibitor monotherapy
GLP-1 Receptor Agonists
GLP-1 Receptor Agonist monotherapy
SGLT-2 inhibitor
SGLT-2 inhibitor monotherapy
insulin
Insulin monotherapy
MET + SU
MET + SU combination
MET + DPP-4 inhibitor
MET + DPP-4 inhibitor combination
MET + GLP-1RA
MET + GLP-1RA combination
MET + SGLT2i
MET + SGLT2i combination
MET + INS
MET + insulin combination
Locations (1)
Pécs
Pécs, Hungary